Thermo Fisher Scientific to acquire Mesa Biotech, gaining COVID-19 testing platform
Thermo Fisher Scientific to acquire Mesa Biotech, gaining COVID-19 testing platform Thermo Fisher Scientific will acquire San Diego molecular diagnostics company Mesa Biotech for approximately $450m in cash, with up to an additional $100m upon completion of certain milestones. Privately held Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. Its patented technology expands the availability of...
Source: biopharma-reporter.com